Camargo Pharmaceutical Services, an industry-leading drug development and commercialization services company, today announced it will expand its capabilities to offer full-service, end-to-end support to drug developers facing complex technical, regulatory and commercial challenges.
CINCINNATI, /PRNewswire/ -- Camargo Pharmaceutical Services, an industry-leading drug development and commercialization services company, today announced it will expand its capabilities to offer full-service, end-to-end support to drug developers facing complex technical, regulatory and commercial challenges. To spearhead the expansion strategy, Carter Gaither, an existing member of Camargo’s executive team, has been named Head of Corporate Development. The company will aggressively expand services both organically and through acquisitions, in partnership with its current shareholder base, according to Dan Duffy, CEO. Camargo’s expansion strategy builds on the Company’s roots, as established by co-founders Ken Phelps and Ruth Stevens, working with biotech and pharmaceutical companies to obtain approval of commercially viable New Drug Applications under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act. This expertise is an important part of the expanded service offerings and will remain core to Camargo’s mission to get medicines to the people who need them. “This is the right time for Camargo Pharmaceutical Services to expand its presence in the drug development industry,” said Duffy. “We believe there is a significant opportunity to leverage our knowledge in drug approvals to expand our European operations, and to become very active in acquiring and growing service lines to deliver on our vision. Carter is the right person to guide this new expansion strategy. He has the depth of experience, knowledge of the industry, and respect from his peers to lead this initiative.” Gaither joined Camargo in 2015 as the Chief Financial Officer and is an experienced financial executive, spending the majority of his career focused on venture-backed and emerging companies in the health care sector. Prior to joining Camargo, he was the managing director of Union Springs Pharmaceuticals and has worked in leadership roles in the venture capital markets. “I look forward to helping Camargo Pharmaceutical Services meet the growing needs of our current clients, sponsors and drug developers in the U.S., Europe and around the world,” said Gaither. “It’s an exciting time with new opportunities for partnership in the drug development industry.” About Camargo Pharmaceutical Services Founded in 2003, Camargo Pharmaceutical Services is a leading global development and commercialization partner to large and small biotech and pharmaceutical companies, with a proven ability to help bring life-changing therapies to the market faster and more cost-effectively. Camargo is established as one of the recognized experts and industry leaders in designing complex, customized development strategies, including those utilizing the FDA 505(b)(2) approval pathway. The company is passionate about the client’s success and the differences it can make in the lives of others. Camargo’s global reach and client base extends to more than 25 countries. Camargo is headquartered in Cincinnati, Ohio. For more about Camargo Pharmaceutical Services, visit http://camargopharma.com.
SOURCE Camargo Pharmaceutical Services |